MGO One Seven LLC Has $13.42 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Key Points

• MGO One Seven LLC increased its holdings in Johnson & Johnson by 5.8% to own 80,891 shares worth $13.4 million, highlighting institutional investor interest in the stock.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, with a current yield of 3.11% and a payout ratio of 55.61%.
• The stock has received mostly positive analyst ratings, with the consensus price target set at $174.50 and various ratings reflecting a trend toward buying.

MGO One Seven LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 80,891 shares of the company's stock after acquiring an additional 4,449 shares during the period. MGO One Seven LLC's holdings in Johnson & Johnson were worth $13,415,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of JNJ. Cordatus Wealth Management LLC grew its position in Johnson & Johnson by 5.6% in the 1st quarter. Cordatus Wealth Management LLC now owns 33,669 shares of the company's stock valued at $5,583,000 after buying an additional 1,791 shares in the last quarter. Atlas Wealth LLC lifted its holdings in Johnson & Johnson by 12.2% in the 1st quarter. Atlas Wealth LLC now owns 2,086 shares of the company's stock valued at $346,000 after acquiring an additional 226 shares during the last quarter. Hoxton Planning & Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $543,000. RVW Wealth LLC lifted its holdings in Johnson & Johnson by 83.7% in the 1st quarter. RVW Wealth LLC now owns 2,612 shares of the company's stock valued at $433,000 after acquiring an additional 1,190 shares during the last quarter. Finally, Peninsula Asset Management Inc. lifted its holdings in Johnson & Johnson by 17.0% in the 1st quarter. Peninsula Asset Management Inc. now owns 1,930 shares of the company's stock valued at $320,000 after acquiring an additional 280 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

JNJ stock traded up $2.32 during midday trading on Monday, hitting $169.65. The stock had a trading volume of 4,937,506 shares, compared to its average volume of 9,047,776. The firm has a market capitalization of $408.57 billion, a price-to-earnings ratio of 18.14, a P/E/G ratio of 2.13 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a 50-day simple moving average of $157.46 and a 200 day simple moving average of $156.74. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on JNJ shares. Guggenheim reissued a "neutral" rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.